iCAD (ICAD) appoints Mark Koeniguer as CCO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
April 8, 2025 10:19 AM EDTNASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer cant hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.
As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field... More
